Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 37-42

  Keith, Robert L ^a,b   Karoor, Vijaya ^b   Mozer, Anthony B ^a   Hudish, Tyler M ^a   Le, Mysan ^a   Miller, York E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemoprevention; EGFR; Gefitinib; Lung cancer; Prostacyclin; Src; Transgenic mice

Indexed keywords

GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTACYCLIN SYNTHASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CYTOCHROME P-450 ENZYME SYSTEM; DINOPROSTONE; EPOPROSTENOL; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77956188663     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.004     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Tong L., Spitz M.R., Fueger J.J., Amos C.A. Lung carcinoma in former smokers. Cancer 1996, 78:1004-1010.
3. Malkinson A.M. Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer 2001, 32:265-279.
4. Stearman R.S., Dwyer-Nield L., Zerbe L., Blaine S.A., Chan Z., Bunn P.A., et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005, 167:1763-1775.
5. Keith R.L., Miller Y.E., Hoshikawa Y., Moore M.D., Gesell T.L., Gao B., et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002, 62:734-740.
6. Keith R.L., Miller Y.E., Hudish T.M., Girod C.E., Sotto-Santiago S., Franklin W.A., et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004, 64:5897-5904.
7. Nemenoff R., Meyer A.M., Hudish T.M., Mozer A.B., Snee A., Narumiya S., et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res 2008, 1:349-356.
8. Merrick D.T., Kittelson J., Winterhalder R., Kotantoulas G., Ingeberg S., Keith R.L., et al. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res 2006, 12:2281-2288.
9. Jonsson S., Varella-Garcia M., Miller Y.E., Wolf H.J., Byers T., Braudrick S., et al. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am J Respir Crit Care Med 2008, 177:342-347.
10. Kurie J.M., Shin H.J., Lee J.S., Morice R.C., Ro J.Y., Lippman S.M., et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996, 2:1787-1793.
11. Tang X., Shigematsu H., Bekele B.N., Roth J.A., Minna J.D., Hong W.K., et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005, 65:7568-7572.
12. Yan Y., Lu Y., Wang M., Vikis H., Yao R., Wang Y., et al. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 2006, 4:971-981.
13. Fujimoto N., Wislez M., Zhang J., Iwanaga K., Dackor J., Hanna A.E., et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005, 65:11478-11485.
14. Kishino D., Kiura K., Takigawa N., Katayama H., Kuyama S., Sato K., et al. Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. Lung Cancer 2009, 65:284-289.
15. Ohashi K., Rai K., Fujiwara Y., Osawa M., Hirano S., Takata K., et al. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Sci 2008, 99:1747-1753.
16. Ohashi K., Takigawa N., Osawa M., Ichihara E., Takeda H., Kubo T., et al. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res 2009, 69:7088-7095.
17. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66:944-950.
18. Wick M., Hurteau G., Dessev C., Chan D., Geraci M.W., Winn R.A., et al. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002, 62:1207-1214.
19. Geraci M.W., Gao B., Shepherd D.C., Moore M.D., Westcott J.Y., Fagan K.A., et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999, 103:1509-1515.
20. Zerbe L.K., Dwyer-Nield L.D., Fritz J.M., Redente E.F., Shroyer R.J., Conklin E., et al. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol 2008, 62:605-620.
21. Zhang X., Chen Z.G., Choe M.S., Lin Y., Sun S.Y., Wieand H.S., et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005, 11:6261-6269.
22. Zhang X., Zhang H., Tighiouart M., Lee J.E., Shin H.J., Khuri F.R., et al. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008, 123:1005-1014.
23. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999, 91:1194-1210.
24. Mueller K.L., Hunter L.A., Ethier S.P., Boerner J.L. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008, 68:3314-3322.
25. Qin B., Ariyama H., Baba E., Tanaka R., Kusaba H., Harada M., et al. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol 2006, 58:577-584.
26. Zhang J., Kalyankrishna S., Wislez M., Thilaganathan N., Saigal B., Wei W., et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007, 170:366-376.